Unraveling the Multifactorial Etiology and the Potential Strategies to Overcome Sarcopenia
Main Article Content
Abstract
Sarcopenia, characterized by the decline of skeletal muscle mass and function, can have severe consequences for older adults, including disability and frailty. The condition is also linked to various diseases, increased insulin resistance, fatigue, falls, and mortality. Factors such as obesity and myosteatosis (fat infiltration into muscle) play a significant role in driving sarcopenia, particularly in morbidly obese individuals who also have low muscle mass, known as sarcopenic obesity. The Framingham study found additional limitations in function and mobility in individuals with sarcopenic obesity. This literature review aims to provide the potential causes of sarcopenia, with a specific focus on middle-aged adults, the biological processes that lead to muscle loss, methods to mitigate its effects, and how physical activity and nutrition can aid in recovery.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. A. J. Cruz-Jentoft et al., "Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis," Age Ageing, vol. 48, no. 1, pp. 16-31, 2019.
II. H. Nishikawa, S. Fukunishi, A. Asai, K. Yokohama, S. Nishiguchi, and K. Higuchi, "Pathophysiology and mechanisms of primary sarcopenia," Int. J. Mol. Med., vol. 48, no. 2, pp. 1-8, 2021.
III. R. Cannataro et al., "Sarcopenia: Etiology, nutritional approaches, and miRNAs," Int. J. Mol. Sci., vol. 22, no. 18, p. 9724, 2021.
IV. I. Liguori et al., "Sarcopenia: assessment of disease burden and strategies to improve outcomes," Clin Interv Aging, vol. 13, p. 913, 2018.
V. N. Hishikawa et al., "Foot orthosis treatment improves physical activity but not muscle quantity in patients with concurrent rheumatoid arthritis and sarcopenia," Mod. Rheumatol., vol. 31, no. 5, pp. 997-1003, 2021.
VI. M. Ebadi, R. A. Bhanji, V. C. Mazurak, and A. J. Montano-Loza, "Sarcopenia in cirrhosis: from pathogenesis to interventions," J. Gastroenterol, vol. 54, no. 10, pp. 845-859, 2019.
VII. F. Bellanti et al., "Oxidative stress is increased in sarcopenia and associated with cardiovascular disease risk in sarcopenic obesity," Maturitas, vol. 109, pp. 6-12, 2018.
VIII. C. Van Aller et al., "Sarcopenic obesity and overall mortality: results from the application of novel models of body composition phenotypes to the National Health and Nutrition Examination Survey 1999–2004," Clinical nutrition, vol. 38, no. 1, pp. 264-270, 2019.
IX. A. Seol, S. I. Kim, and Y. S. Song, "Sarcopenia: clinical implications in ovarian cancer, diagnosis, etiology, and management," SMHS, vol. 2, no. 4, pp. 202-210, 2020.
X. A. D. Ardeljan and R. Hurezeanu, "Sarcopenia," in StatPearls [Internet]: StatPearls Publishing, 2022.
XI. S.-Y. Lee, H.-H. Tung, C.-Y. Liu, and L.-K. Chen, "Physical activity and sarcopenia in the geriatric population: a systematic review,"JAMDA, vol. 19, no. 5, pp. 378-383, 2018.
XII. J. L. Perez-Lasierra, J. A. Casajus, A. González-Agüero, and B. Moreno-Franco, "Association of physical activity levels and prevalence of major degenerative diseases: Evidence from the national health and nutrition examination survey (NHANES) 1999–2018," Exp. Gerontol, vol. 158, p. 111656, 2022.
XIII. N. F. Meier and D.-c. Lee, "Physical activity and sarcopenia in older adults," Aging Clin Exp Res, vol. 32, no. 9, pp. 1675-1687, 2020.
XIV. K. Yuenyongchaiwat and R. Boonsinsukh, "Sarcopenia and its relationships with depression, cognition, and physical activity in Thai community-dwelling older adults," Curr Gerontol Geriatr Res, vol. 2020, 2020.
XV. A. Del Campo et al., "Muscle function decline and mitochondria changes in middle age precede sarcopenia in mice," Aging (Albany NY), vol. 10, no. 1, p. 34, 2018.
XVI. K. Ma, F. Huang, R. Qiao, and L. Miao, "Pathogenesis of sarcopenia in chronic obstructive pulmonary disease," Front. Physiol., vol. 13, 2022.
XVII. Z. Liang et al., "Inflammaging: The ground for sarcopenia?," Exp. Gerontol, p. 111931, 2022.
XVIII. W.-S. Jung, Y.-Y. Kim, J.-W. Kim, and H.-Y. Park, "Effects of Circuit Training Program on Cardiovascular Risk Factors, Vascular Inflammatory Markers, and Insulin-like Growth Factor-1 in Elderly Obese Women with Sarcopenia," RCM, vol. 23, no. 4, p. 134, 2022.
XIX. F. Riuzzi et al., "Cellular and molecular mechanisms of sarcopenia: the S100B perspective," J. Cachexia Sarcopenia Muscle, vol. 9, no. 7, pp. 1255-1268, 2018.
XX. A. Frisoli Jr, F. G. Martin, A. C. d. C. Carvalho, J. Borges, A. T. Paes, and S. J. M. Ingham, "Sex effects on the association between sarcopenia EWGSOP and osteoporosis in outpatient older adults: data from the SARCOS study," AE&M , vol. 62, pp. 615-622, 2018.
XXI. P. J. Marcos-Pardo et al., "Sarcopenia, diet, physical activity and obesity in european middle-aged and older adults: The lifeage study," Nutrients, vol. 13, no. 1, p. 8, 2020.
XXII. P. P. Coll, S. Phu, S. H. Hajjar, B. Kirk, G. Duque, and P. Taxel, "The prevention of osteoporosis and sarcopenia in older adults," JAGS, vol. 69, no. 5, pp. 1388-1398, 2021.
XXIII. P. Liczbiński and B. Bukowska, "Molecular mechanism of amygdalin action in vitro: review of the latest research," Immunopharmacol Immunotoxicol, vol. 40, no. 3, pp. 212-218, 2018.
XXIV. M. E. Csete, "Basic Science of Frailty—Biological Mechanisms of Age-Related Sarcopenia," Anesth. Analg., vol. 132, no. 2, pp. 293-304, 2021.
XXV. P. M. Coen, R. V. Musci, J. M. Hinkley, and B. F. Miller, "Mitochondria as a target for mitigating sarcopenia," Front. Physiol., vol. 9, p. 1883, 2019.
XXVI. J. Yin, X. Lu, Z. Qian, W. Xu, and X. Zhou, "New insights into the pathogenesis and treatment of sarcopenia in chronic heart failure," Theranostics, vol. 9, no. 14, p. 4019, 2019.
XXVII. S. Song, E. W. F. Lam, T. Tchkonia, J. L. Kirkland, and Y. Sun, "Senescent cells: emerging targets for human aging and age-related diseases," TIBS, vol. 45, no. 7, pp. 578-592, 2020.
XXVIII. C. M. Nascimento, M. Ingles, A. Salvador-Pascual, M. R. Cominetti, M. C. Gomez-Cabrera, and J. Viña, "Sarcopenia, frailty and their prevention by exercise," Free Radic Biol Med, vol. 132, pp. 42-49, 2019.
XXIX. E. A. Greco, P. Pietschmann, and S. Migliaccio, "Osteoporosis and sarcopenia increase frailty syndrome in the elderly," Front. Endocrinol., vol. 10, p. 255, 2019.
XXX. L. Yang et al., "Comparison of revised EWGSOP criteria and four other diagnostic criteria of sarcopenia in Chinese community-dwelling elderly residents,"Exp. Gerontol., vol. 130, p. 110798, 2020.
XXXI. J. Reiss et al., "Consequences of applying the new EWGSOP2 guideline instead of the former EWGSOP guideline for sarcopenia case finding in older patients," Age Ageing, vol. 48, no. 5, pp. 719-724, 2019.
XXXII. A. Escriche-Escuder, I. J. Fuentes-Abolafio, C. Roldan-Jimenez, and A. I. Cuesta-Vargas, "Effects of exercise on muscle mass, strength, and physical performance in older adults with sarcopenia: a systematic review and meta-analysis according to the EWGSOP criteria," Exp. Gerontol., vol. 151, p. 111420, 2021.
XXXIII. M. M. de Freitas et al., "Difference in sarcopenia prevalence and associated factors according to 2010 and 2018 European consensus (EWGSOP) in elderly patients with type 2 diabetes mellitus," Exp. Gerontol., vol. 132, p. 110835, 2020.
XXXIV. I. Y. Jang et al., "Characteristics of sarcopenia by European consensuses and a phenotype score," J. Cachexia Sarcopenia Muscle, vol. 11, no. 2, pp. 497-504, 2020.
XXXV. M.-H. Jung et al., "Effects of sarcopenia, body mass indices, and sarcopenic obesity on diastolic function and exercise capacity in Koreans," Metab., vol. 97, pp. 18-24, 2019.
XXXVI. L. R. Anastácio et al., "Sarcopenia, obesity and sarcopenic obesity in liver transplantation: a body composition prospective study," ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo), vol. 32, 2019.
XXXVII. H.-W. Jung et al., "Association between serum FGF21 level and sarcopenia in older adults," Bone, vol. 145, p. 115877, 2021.
XXXVIII. M. Locquet, C. Beaudart, J. Petermans, J.-Y. Reginster, and O. Bruyère, "EWGSOP2 versus EWGSOP1: impact on the prevalence of sarcopenia and its major health consequences," JAMDA, vol. 20, no. 3, pp. 384-385, 2019.
XXXIX. H. Trierweiler, G. Kisielewicz, T. Hoffmann Jonasson, R. Rasmussen Petterle, C. Aguiar Moreira, and V. Zeghbi Cochenski Borba, "Sarcopenia: a chronic complication of type 2 diabetes mellitus," Diabetes Metab Syndr, vol. 10, no. 1, pp. 1-9, 2018.
XL. K. Kashiwagi et al., "A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic obesity,"Clin. Nutr. ESPEN, vol. 38, pp. 86-93, 2020.
XLI. E. Roh et al., "Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study," Hepatol. Int., vol. 16, no. 3, pp. 545-554, 2022.
XLII. B. W. J. Pang et al., "Prevalence and associated factors of Sarcopenia in Singaporean adults—the Yishun Study," JAMDA, vol. 22, no. 4, pp. 885-e1, 2021.
XLIII. T. L. da Silva, V. d. S. C. S. Nogueira, and A. P. Mulder, "Sarcopenia and poor muscle quality associated with severe obesity in young adults and middle-aged adults," Clin. Nutr. ESPEN, vol. 45, pp. 299-305, 2021.
XLIV. Y. Du et al., "Associations of physical activity with sarcopenia and sarcopenic obesity in middle-aged and older adults: the Louisiana osteoporosis study," BMC Public Health, vol. 22, no. 1, pp. 1-13, 2022.
XLV. L. V. Fernandes et al., "Recent consensus on definition and diagnosis for sarcopenia (EWGSOP2): agreement with the first consensus (EWGSOP1) and with tools for screening sarcopenia in older women," Nutrire, vol. 46, no. 2, pp. 1-7, 2021.
XLVI. M.-F. Xia et al., "Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study," Clin Nutr, vol. 40, no. 2, pp. 571-580, 2021.
XLVII. J. S. Oliveira et al., "Evidence on physical activity and the prevention of frailty and sarcopenia among older people: a systematic review to inform the World Health Organization physical activity guidelines," JPAH, vol. 17, no. 12, pp. 1247-1258, 2020.
XLVIII. A. Bian et al., "Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly," BMC Musculoskelet. Disord., vol. 21, no. 1, pp. 1-9, 2020.
XLIX. L. V. Fernandes et al., "Prevalence of sarcopenia according to EWGSOP1 and EWGSOP2 in older adults and their associations with unfavorable health outcomes: a systematic review," Aging Clin Exp Re, pp. 1-10, 2021.
L. G.-H. Bai, M.-C. Tsai, H.-W. Tsai, C.-C. Chang, and W.-H. Hou, "Effects of branched-chain amino acid-rich supplementation on EWGSOP2 criteria for sarcopenia in older adults: a systematic review and meta-analysis," Eur, pp. 1-15, 2021.
LI. B. W. J. Pang et al., "Prevalence and associated factors of Sarcopenia in Singaporean adults—the Yishun Study," JAMDA, vol. 22, no. 4, pp. 885-e1, 2021.
LII. Y. Du et al., "Associations of physical activity with sarcopenia and sarcopenic obesity in middle-aged and older adults: the Louisiana osteoporosis study," BMC Public Health, vol. 22, no. 1, pp. 1-13, 2022.
LIII. L. V. Fernandes et al., "Recent consensus on definition and diagnosis for sarcopenia (EWGSOP2): agreement with the first consensus (EWGSOP1) and with tools for screening sarcopenia in older women," Nutrire, vol. 46, no. 2, pp. 1-7, 2021.
LIV. M.-F. Xia et al., "Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study," Clin, vol. 40, no. 2, pp. 571-580, 2021.
LV. J. S. Oliveira et al., "Evidence on physical activity and the prevention of frailty and sarcopenia among older people: a systematic review to inform the World Health Organization physical activity guidelines," JPAH, vol. 17, no. 12, pp. 1247-1258, 2020.
LVI. A. Bian et al., "Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly," BMC Musculoskelet. Disord., vol. 21, no. 1, pp. 1-9, 2020.
LVII. L. V. Fernandes et al., "Prevalence of sarcopenia according to EWGSOP1 and EWGSOP2 in older adults and their associations with unfavorable health outcomes: a systematic review," Aging Clin Exp Res, pp. 1-10, 2021.
LVIII. G.-H. Bai, M.-C. Tsai, H.-W. Tsai, C.-C. Chang, and W.-H. Hou, "Effects of branched-chain amino acid-rich supplementation on EWGSOP2 criteria for sarcopenia in older adults: a systematic review and meta-analysis," Eur. J. Nutr., pp. 1-15, 2021.